SCHEDULE: Tang Capital Shifts to Passive Stake in ESSA Pharma, Reducing Activist Stance

Tang Capital Management and affiliated entities have amended their SEC filing for ESSA Pharma Inc., indicating a shift from an active to a passive investment strategy, no longer seeking to influence company control.

Summary

• Tang Capital Management, LLC, Kevin Tang, and affiliated entities (Tang Capital Partners, LP, Tang Capital Partners International, LP) collectively beneficially own 4,300,000 Common Shares of ESSA Pharma Inc.
• This represents 9.7% of ESSA Pharma Inc.'s outstanding Common Shares, based on 44,338,550 shares as of May 7, 2025.
• The filing is an Amendment No. 1 to a previously filed Schedule 13D, converting it to a Schedule 13G.
• The Reporting Persons state they no longer hold the securities with the purpose or effect of changing or influencing control of ESSA Pharma Inc.
• All beneficially owned shares have shared voting and dispositive power among the reporting persons.

Sentiment

Score: 5

Explanation: The filing is neutral in sentiment, primarily a factual disclosure of a change in investment intent from active to passive. It does not contain positive or negative operational or financial news for the company itself.

Positives

• The filing indicates a clear shift to a passive investment stance by Tang Capital, potentially reducing perceived activist pressure on ESSA Pharma Inc.'s management.

Negatives

• The change from an active Schedule 13D to a passive Schedule 13G could be interpreted by some investors as a reduced conviction in the need for active engagement or a lack of immediate catalysts for change.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding ESSA Pharma Inc.'s future operations or financial performance, focusing solely on the reporting persons' ownership and investment intent.

Management Comments

• The Reporting Persons no longer hold the securities with a purpose or effect of changing or influencing control of the Issuer.

Industry Context

This filing is a standard ownership disclosure and does not provide specific insights into broader industry trends within the biotechnology or pharmaceutical sectors. It primarily reflects an investor's change in strategy regarding a specific company.

Comparison to Industry Standards

• This filing is a regulatory disclosure of ownership and intent, not a performance report. Therefore, direct comparisons to industry-specific financial or operational benchmarks are not applicable.
• The change from a 13D to a 13G filing is a common occurrence for investors who shift from an activist stance to a passive one, aligning with standard SEC reporting requirements for significant shareholders.

Stakeholder Impact

• Shareholders: May perceive reduced activist pressure on management, potentially leading to less volatility related to shareholder activism.

Key Dates

Keywords

ESSA Pharma Inc., Tang Capital Management, Kevin Tang, Schedule 13G, SEC Filing, Beneficial Ownership, Passive Investment, Biotechnology, Pharmaceuticals, Shareholder Disclosure